Webinar video | Life Sciences Session #3: ‘Trop is te veel’: what not to do in case of pricing of medicines?
The COVID-19 pandemic challenges companies and firms worldwide, and requires us all to adopt new proactive approaches. While COVID-19 prevents us from being together, our Life Sciences team takes the initiative to give you short, digestible and regular online Life Sciences Sessions.
Are you trying to see the wood for the trees when setting prices and arranging reimbursement for you medicines in Belgium? Is “the sky the limit” for your medicines’ prices? Or are you also wondering what all the fuzz is about the Commission’s decision towards Aspen?
- Kirian Claeyé will guide you through the regulatory maze of pricing and reimbursement of medicines in Belgium.
- Beatrijs Gielen and Nina Methens will clarify the European Courts’ approach towards excessive pricing under competition law, in particular in the pharma sector, and will discuss the long-awaited European Commission settlement decision in the Aspen case.
Recommended articles
Belgium aims for hospitals to increase their biosimilars uptake
Despite many initiatives by the (former) Minister of Health, the uptake of biosimilars in Belgium has remained rather low. In this blog, we summarise the new rules, which apply since 2 October 2023.
Read on
The Belgian Competition Authority publishes a specific analytical framework for hospital concentrations
This article is an updated version of our previous article on the uncertainty regarding hospital merger control, focusing on the BCA’s decision of 28 June 2023.
Read on
WEBINAR VIDEO | Navigating Mergers and Acquisitions in Life Sciences: Insights for Success and Pitfalls to avoid
During this webinar, the experts from our assembled transactions team, Richard Liu, Mieke D’hanis and Pauline Geentjens, provide valuable insights, inform you of common pitfalls and let you in on a number of tips and tricks during an Mergers and Acquisitions process.
Read on